Skin Pigmentation, Fluence Determine IPL Side Effects

This article originally appeared here.
Share this content:
Skin Pigmentation, Fluence Determine IPL Side Effects
Skin Pigmentation, Fluence Determine IPL Side Effects

FRIDAY, Aug. 5, 2016 (HealthDay News) -- Darker skin pigmentation and increasing intense pulsed light (IPL) fluence determine side effects after IPL exposure, according to a study published online July 30 in Lasers in Surgery and Medicine.

In a study involving 16 healthy subjects with Fitzpatrick skin types (FSTs) II to V, Daniel Thaysen-Petersen, M.D., from the University of Copenhagen in Denmark, and colleagues examined the contribution of skin pigmentation, fluence level, and ultraviolet radiation (UVR) on IPL-induced side effects. Three test areas were separated into four sites and randomly allocated to a single IPL exposure of 22, 34, and 46 J/cm² or triple stacking of 46 J/cm²; subsequently, areas were randomized to no UVR or single solar-simulated UVR exposure. Each area had a corresponding control. Patients were followed for up to four weeks after IPL.

The protocol was completed by 15 subjects with FSTs II to IV. The researchers found that IPL induced a range of skin reactions, including erythema (87 percent), hyper- and hypopigmentation (60 and 20 percent, respectively), purpura (27 percent), blisters (20 percent), edema (13 percent), and crusting (13 percent). Determinants for IPL-induced side effects included darker skin pigmentation and increasing IPL fluence (P ≤ 0.002); side effects were not exacerbated with single exposure of UVR (P ≥ 0.180).

"Skin pigmentation and IPL fluence are major determinants of side effects after IPL exposure," the authors write.

Several authors disclosed financial ties to The Proctor & Gamble Company, which funded the study.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

FDA Approves Bavencio for Merkel Cell Carcinoma

FDA Approves Bavencio for Merkel Cell Carcinoma

Drug targets the PD-1/PD-L1 pathway; first sanctioned treatment in the United States

Heterogeneous Association for Alcohol, CVD Presentation

Heterogeneous Association for Alcohol, CVD Presentation

Non-drinking linked to increased risks of unstable angina, MI, heart failure, ischemic stroke, PAD, AAA

Mobile App Cuts In-Person Visits After Breast Reconstruction

Mobile App Cuts In-Person Visits After Breast Reconstruction

Number of visits down, increase in e-mails to doctors for ambulatory patients undergoing breast recon

is free, fast, and customized just for you!

Already a member?

Sign In Now »